Oppenheimer Upgrades Genoptix (GXDX) to Outperform
More News related to GXDX
- Genoptix Announces Participation at Lazard Capital Management 6th Annual Healthcare Conference
- Auriga Reiterates a 'Buy' on Genoptix (GXDX); Unique Growth Story
- Genoptix (GXDX) Rops Q3 EPS by 21c; Guides Higher for FY09; 2010 Revs In-line
- Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
More News related to Upgrades
- LTX-Credence (LTXC) Files $100 Mixed Shelf
- Metabolix (MBLX) Commences Common Stock Public Offering
- Praxair (PX) Prices $400M of 1.75% Notes
- General Cable (BGC) Extends Expiration Date of Its Convertible Note Exchange Offer
- First Defiance Financial (FDEF) Files $80M Shelf Registration
Oppenheimer upgrades Genoptix (Nasdaq: GXDX) from Perform to Outperform. Price target increased from $33 to $44.
To see more analyst ratings on GXDX Click Here.
Genoptix, Inc. (Genoptix) is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists (hema/oncs).
Related Categories
UpgradesStocks Mentioned
-0.44Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
